In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects.
The European Chemicals Bureau and the Organisation for Economic Cooperation and Development are currently compiling a sanctioned list of quantitative structure-activity relationship (QSAR) risk assessment models and data sets to predict the physiological properties, environmental fate, ecological effects and human health effects of new and existing chemicals in commerce in the European Union. This action implements the technical requirements of the European Commission's Registration, Evaluation and Authorisation of Chemicals legislation. The goal is to identify a battery of QSARs that can furnish rapid, reliable and cost-effective decision support information for regulatory decisions that can substitute for results from animal studies. This report discusses issues and concerns that need to be addressed when selecting QSARs to predict human health effect end points.
Matthews
Edwin J
EJ
US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA. Edwin.Matthews@fda.hhs.gov
Contrera
Joseph F
JF
D000826:Animal Testing Alternatives / Q000379:methods / Q000592:standards; D000818:Animals; D003198:Computer Simulation; D064420:Drug-Related Side Effects and Adverse Reactions; D017408:Guidelines as Topic; D006801:Humans; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000737:chemistry; D011634:Public Health; D021281:Quantitative Structure-Activity Relationship; D018570:Risk Assessment / Q000379:methods
D004364:Pharmaceutical Preparations